Mark T. Linthicum
Precision Health Economics
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark T. Linthicum.
Chest | 2015
Julia Thornton Snider; Anupam B. Jena; Mark T. Linthicum; Refaat A. Hegazi; J. Partridge; Chris LaVallee; Darius N. Lakdawalla; Paul E. Wischmeyer
BACKGROUND COPD is a leading cause of death and disability in the United States. Patients with COPD are at a high risk of nutritional deficiency, which is associated with declines in respiratory function, lean body mass and strength, and immune function. Although oral nutritional supplementation (ONS) has been associated with improvements in some of these domains, the impact of hospital ONS on readmission risk, length of stay (LOS), and cost among hospitalized patients is unknown. METHODS Using the Premier Research Database, we first identified Medicare patients aged ≥ 65 years hospitalized with a primary diagnosis of COPD. We then identified hospitalizations in which ONS was provided, and used propensity-score matching to compare LOS, hospitalization cost, and 30-day readmission rates in a one-to-one matched sample of ONS and non-ONS hospitalizations. To further address selection bias among patients prescribed ONS, we also used instrumental variables analysis to study the association of ONS with study outcomes. Model covariates included patient and provider characteristics and a time trend. RESULTS Out of 10,322 ONS hospitalizations and 368,097 non-ONS hospitalizations, a one-to-one matched sample was created (N = 14,326). In unadjusted comparisons in the matched sample, ONS use was associated with longer LOS (8.7 days vs 6.9 days, P < .0001), higher hospitalization cost (
Journal of Parenteral and Enteral Nutrition | 2014
Julia Thornton Snider; Mark T. Linthicum; Yanyu Wu; Chris LaVallee; Darius N. Lakdawalla; Refaat Hegazi; Laura E. Matarese
14,223 vs
Journal of Parenteral and Enteral Nutrition | 2014
Darius N. Lakdawalla; Maria R. Mascarenhas; Anupam B. Jena; Jacqueline Vanderpuye-Orgle; Chris LaVallee; Mark T. Linthicum; Julia Thornton Snider
9,340, P < .0001), and lower readmission rates (24.8% vs 26.6%, P = .0116). However, in instrumental variables analysis, ONS use was associated with a 1.9-day (21.5%) decrease in LOS, from 8.8 to 6.9 days (P < .01); a hospitalization cost reduction of
Asia-Pacific Journal of Public Health | 2015
Mark T. Linthicum; Julia Thornton Snider; Rhema Vaithianathan; Yanyu Wu; Chris LaVallee; Darius N. Lakdawalla; Jennifer Benner; Tomas Philipson
1,570 (12.5%), from
Health Affairs | 2014
Gery W. Ryan; Evan W. Bloom; David J. Lowsky; Mark T. Linthicum; Timothy Juday; Lisa Rosenblatt; Sonali Kulkarni; Dana P. Goldman; Jennifer N. Sayles
12,523 to
Health Affairs | 2015
Warren Stevens; Tomas Philipson; Zeba M. Khan; Joanna P. MacEwan; Mark T. Linthicum; Dana P. Goldman
10,953 (P < .01); and a 13.1% decrease in probability of 30-day readmission, from 0.34 to 0.29 (P < .01). CONCLUSIONS ONS may be associated with reduced LOS, hospitalization cost, and readmission risk in hospitalized Medicare patients with COPD.
Journal of Parenteral and Enteral Nutrition | 2014
Tomas Philipson; Mark T. Linthicum; Julia Thornton Snider
BACKGROUND The burden imposed by disease-associated malnutrition (DAM) on patients and the healthcare system in food-abundant industrialized countries is often underappreciated. This study measured the economic burden of community-based DAM in the United States. METHODS The burden of DAM was quantified in terms of direct medical costs, quality-adjusted life years lost, and mortality across 8 diseases (breast cancer, chronic obstructive pulmonary disease [COPD], colorectal cancer [CRC], coronary heart disease [CHD], dementia, depression, musculoskeletal disorders, and stroke). To estimate the total economic burden, the morbidity and mortality burden was monetized using a standard value of a life year and combined with direct medical costs of treating DAM. Disease-specific prevalence and malnutrition estimates were taken from the National Health Interview Survey and the National Health and Nutrition Examination Survey. Deaths by disease were taken from the Center for Disease Control and Prevention. Estimates of costs and morbidity were taken from the literature. RESULTS The annual burden of DAM across the 8 diseases was
Forum for Health Economics & Policy | 2014
Darius N. Lakdawalla; Julia Thornton Snider; Daniella Perlroth; Chris LaVallee; Mark T. Linthicum; Tomas Philipson; J. Partridge; Paul E. Wischmeyer
156.7 billion, or
Journal of Comparative Effectiveness Research | 2015
Michael Eber; Dana P. Goldman; Darius N. Lakdawalla; Tomas Philipson; Daryl Pritchard; Marco D. Huesch; Nicholas Summers; Mark T. Linthicum; Jeff Sullivan; Robert W. Dubois
508 per U.S. resident. Nearly 80% of this burden was derived from morbidity associated with DAM; around 16% derived from mortality and the remainder from direct medical costs of treating DAM. The total burden was highest in COPD and depression, while the burden per malnourished individual was highest in CRC and CHD. CONCLUSION DAM exacts a large burden on American society. Therefore, improved diagnosis and management of community-based DAM to alleviate this burden are needed.
Journal of Managed Care Pharmacy | 2018
James R. Baumgardner; Ahva Shahabi; Mark T. Linthicum; Seanna Vine; Christopher Zacker; Darius N. Lakdawalla
BACKGROUND Nutrition deficiency is common among hospitalized children. Although oral nutrition supplements (ONS) may improve malnutrition in this population, the benefits and healthcare costs associated with their use have not yet been fully explored. The objective of this study was to assess the effect of ONS use on inpatient length of stay (LOS) and episode cost in hospitalized children. MATERIALS AND METHODS Retrospective analysis of 557,348 hospitalizations of children aged 2-8 years in the Premier Research Database. The effect of ONS use on LOS and episode cost in a propensity score- matched sample was estimated in analyses with and without the use of instrumental variables (IVs) to reduce confounding from unobserved variables. RESULTS ONS were prescribed in 6066 of 557,348 inpatient episodes (1.09%). In IV analysis, using a matched sample of 11,031 episodes, hospitalizations with ONS use had 14.8% shorter LOS (6.4 vs 7.5 days; 1.1 days [95% CI, 0.2-2.4]). Hospitalizations with ONS use had 9.7% lower cost (